Myasthenia gravis is an autoimmune disease characterized by antibody formation against postsynaptic acetylcholine receptors. Patients demonstrate increased sensitivity to nondepolarizing muscle relaxants. Sugammadex is a new selective nondepolarizing muscle relaxant-binding agent designed to reverse the effect of steroidal muscle relaxants like rocuronium and vecuronium. This article reports the use of 4 mg kg-1 Sugammadex to reverse neuromuscular blockade in a myasthenia gravis case, where 0.6 mg kg-1 rocuronium was used as a neuromuscular blocking agent.
Keywords: Myasthenia gravis, sugammadex, rocuronium